Related Experiment Video

Updated: Mar 19, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

Disrupting the endothelin and Wnt relationship to overcome chemoresistance

Laura Rosanò1, Anna Bagnato1

  • 1Molecular Pathology Laboratory; Regina Elena National Cancer Institute ; Rome, Italy.

Molecular & Cellular Oncology
|June 17, 2016
PubMed

Insights

Targeting the endothelin A receptor and β-arrestin-1 pathway can overcome chemotherapy resistance in ovarian cancer. This finding supports endothelin-1 receptor antagonists as a promising therapeutic strategy for ovarian cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Chemoresistance remains a significant challenge in ovarian cancer treatment.
  • Understanding chemoresistance mechanisms is crucial for developing effective therapies.
  • The Wnt/β-catenin pathway plays a role in ovarian cancer progression and chemoresistance.

Purpose of the Study:

  • To investigate the role of the endothelin A receptor/β-arrestin-1 pathway in ovarian cancer chemoresistance.
  • To determine if targeting this pathway can sensitize ovarian cancer to chemotherapy.

Main Methods:

  • The study focused on the interaction between endothelin A receptor and β-arrestin-1.
  • Investigated the link between this complex and the Wnt/β-catenin pathway.
  • Assessed the effect of targeting this pathway on chemotherapy sensitivity in ovarian cancer models.

Main Results:

  • Targeting the endothelin A receptor/β-arrestin-1 complex was found to be sufficient to sensitize ovarian cancer to chemotherapy.
  • This pathway is a key regulator of chemoresistance in ovarian cancer.
  • The interaction with Wnt/β-catenin was highlighted as a critical component.

Conclusions:

  • The endothelin A receptor/β-arrestin-1 pathway is a viable therapeutic target for overcoming chemoresistance in ovarian cancer.
  • Endothelin-1 receptor antagonists show potential as novel anticancer drugs for ovarian cancer.
Keywords:
chemoresistanceendothelin-1epithelial ovarian cancerβ-arrestin-1β-catenin

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.7K
The Soft Agar Colony Formation Assay08:01

The Soft Agar Colony Formation Assay

Published on: October 27, 2014

114.3K

Related Concept Videos

Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
10.9K
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

2.6K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
8.6K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

1.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.9K